Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose
Latest Information Update: 15 Apr 2025
At a glance
- Drugs Bevacizumab (Primary)
- Indications Epistaxis; Hereditary haemorrhagic telangiectasia
- Focus Therapeutic Use
- Acronyms EROSB
Most Recent Events
- 11 Apr 2025 Status changed from recruiting to completed.
- 02 Oct 2020 Planned End Date changed from 1 Jan 2017 to 1 Dec 2021.
- 02 Oct 2020 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2020.